References
- Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol. 2000;1:89–99.
- Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995–1007.
- Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 1995;80:233–238.
- Erenus M, Yucelten D, Gurbuz O, Durmusoglu F, Pekin S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril. 1996;66:216–219.
- Mowszowicz I, Wright F, Vincens M, Rigaud C, Nahoul K, Mavier P, Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem. 1986;20:757–761.
- Marcondes JA, Waychenberg BL, Abujamra AG, Luthold WW, Samojlik E, Kirschner MA. Monthly cyproterone acetate in the treatment of hirsute women: Clinical and laboratory effects. Fertil Steril. 1990;53:40–44.
- Kelestimur F, Sahin H. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 1998;69:66–69.
- Hatch R, Rosenfield RL, Kim MH, Teadway D. Hirsutism: Implications, etiology and management. Am J Obstet Gynecol. 1981;140:815–830.
- The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
- Yildiz BO. Assessment, diagnosis and treatment of a patient with hirsutism. Nat Clin Pract Endocrinol Metab. 2008;4:294–300.
- Claman P, Graves GR, Kredentser JV, Sagle MA, Tan S, Tummon I, Fluker M; Reproductive Endocrinology Infertility Committee and Executive Committeee and Council, Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2002;24:62–73, 77-9.
- Calaf J, Lopez E, Millet A, Alcaniz J, Fortuny A, Vidal O, Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: A 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007;92:3446–3452.
- Batukan C, Muderris I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2005;85:436–440.
- Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: Opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592–1597.
- Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–2823.
- Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38.
- Porcile A, Gallardo E. Long-term treatment of hirsutism desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril. 1991;55:877–881.
- Falsetti L, Ramazzotto F, Rosina B. Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome. J Obstet Gynaecol. 1997;17:565–568.
- Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos P, Giannikos L. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: A randomized controlled trial. Gynecol Endocrinol. 1996;10:119–123.
- Jasonni VM, Bulletti C, Naldi S, Di Cosmo E, Cappuccini F, Flamigni C. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β-estradiol. Fertil Steril. 1991;55:742–745.